the New York Times
). He is also the co-founder of a
non-profit organization called The International Partnership for Critical
Markers of Disease to promote the development, evaluation, and appropriate
clinical utilization of biomarkers. Dr. Libby earned his medical degree at
the University of California, San Diego, and completed his training in
internal medicine and cardiology at the Peter Bent Brigham Hospital (now
Brigham and Women's Hospital).
A live audiovisual webcast of the presentation can be accessed from the
investor section of the VIA website, http://www.viapharmaceuticals.com
beginning at 12:00pm EDT on Tuesday, September 16. The webcast will be
archived for at least 14 days following the presentation.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the
development of compounds for the treatment of cardiovascular disease. VIA
is building a pipeline of small-molecule drugs that target a significant
unmet medical need: reducing inflammation in the blood vessel wall, which
is an underlying cause of atherosclerosis and its complications, including
heart attack and stroke. The company's lead drug candidate, VIA-2291, is in
Phase 2 clinical studies in patients with cardiovascular disease. For
more information, visit: http://www.viapharmaceuticals.com.
This press release may contain "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements relate to future events or to VIA's future financial performance
and involve known and unknown risks, uncertainties and other factors that
may cause VIA's actual results, levels of activit
Page: 1 2 3 4 Related biology technology :1
|SOURCE VIA Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes2
. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results3
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML4
. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20075
. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results6
. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences7
. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer8
. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences9
. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals10
. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)11
. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs